TMD Energy Board Changes, Kwok On Tse Appointed Independent Director
TMD Energy, together with its subsidiaries, announced changes to its board of directors. The Board announces that, on February 16, 2026, Shin Yick Fabian resigned as an independent Director. Upon his resignation, Shin Yick Fabian ceased to serve as chairman of the nominating and corporate governance committee of the Board and as a member of each of the audit committee of the Board and the compensation committee of the Board. Shin Yick Fabian's resignation was due to personal reasons and was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies, procedures or practices. To fill the vacancy created by Shin Yick Fabian's resignation, the Board appointed Kwok On Tse as an independent Director on February 16, 2026.
Trade with 70% Backtested Accuracy
Analyst Views on TMDE
About TMDE
About the author
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
Sequans Communications Investment: Shares of Sequans Communications rose 42.2% in pre-market trading after announcing a $384 million strategic investment for a bitcoin treasury initiative.
Market Movements: Several stocks experienced significant changes in pre-market trading, with OceanPal Inc. surging 86.1% and COMPASS Pathways PLC dropping 30.8%.
TMD Energy Limited Enters into Strategic Memorandum of Agreement to Advance Green Bioenergy Collaboration
Partnership Announcement: TMD Energy Limited has signed a Memorandum of Agreement with Double Corporate Sdn Bhd to explore collaboration in sustainable bioenergy solutions for the EU and Asia markets, focusing on integrating alternative fuel energy sectors.
Company Backgrounds: Double Corporate specializes in converting waste into high-yield sustainable fuels using ISCC-EU-approved technology, while TMD Energy Limited provides marine fuel bunkering services across 19 ports in Malaysia.
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Incyte Corporation's Stock Surge: Incyte shares rose 9.6% to $74.25 in pre-market trading following a collaboration announcement with QIAGEN to develop companion diagnostics for mutant CALR-expressing Myeloproliferative Neoplasms.
Pre-Market Trading Highlights: Several stocks experienced significant movements, including TMD Energy Limited (+203%), Regencell Bioscience Holdings (+169.6%), and Sarepta Therapeutics (-31.4%) after halting shipments and trials due to safety concerns.
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories
Market Update: The trading week is nearing its end, but there are still significant stock market developments to follow on Friday.
Resource for Traders: TipRanks provides a list of the hottest market happenings and offers a guide to finding the best online brokers for trading.
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
Sequans Communications Investment: Shares of Sequans Communications rose 42.2% in pre-market trading after announcing a $384 million strategic investment for a bitcoin treasury initiative.
Market Movements: Several stocks experienced significant changes in pre-market trading, with OceanPal Inc. surging 86.1% and COMPASS Pathways PLC dropping 30.8%.
TMD Energy Limited Enters into Strategic Memorandum of Agreement to Advance Green Bioenergy Collaboration
Partnership Announcement: TMD Energy Limited has signed a Memorandum of Agreement with Double Corporate Sdn Bhd to explore collaboration in sustainable bioenergy solutions for the EU and Asia markets, focusing on integrating alternative fuel energy sectors.
Company Backgrounds: Double Corporate specializes in converting waste into high-yield sustainable fuels using ISCC-EU-approved technology, while TMD Energy Limited provides marine fuel bunkering services across 19 ports in Malaysia.
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Incyte Corporation's Stock Surge: Incyte shares rose 9.6% to $74.25 in pre-market trading following a collaboration announcement with QIAGEN to develop companion diagnostics for mutant CALR-expressing Myeloproliferative Neoplasms.
Pre-Market Trading Highlights: Several stocks experienced significant movements, including TMD Energy Limited (+203%), Regencell Bioscience Holdings (+169.6%), and Sarepta Therapeutics (-31.4%) after halting shipments and trials due to safety concerns.
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories
Market Update: The trading week is nearing its end, but there are still significant stock market developments to follow on Friday.
Resource for Traders: TipRanks provides a list of the hottest market happenings and offers a guide to finding the best online brokers for trading.
